CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 5, 2017--
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical
oncology company advancing a broad pipeline of novel product candidates
based on its Targeting Protein Therapeutics (TPTs) platform, today
announced that Stephen Hurly, President and Chief Executive Officer,
will present a company overview at the Rodman & Renshaw 19th
Annual Global Investment Conference in New York on Monday, September 11,
2017 at 3:00 p.m. EDT.
A live webcast can be accessed from the Investors & Media section of
Eleven's website, www.elevenbio.com.
An archived replay of the webcast will be available on the Company's
website for 90 days after the conference.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a late-stage clinical oncology company
advancing a broad pipeline of novel product candidates based upon the
Company's targeted protein therapeutics (TPTs) platform. The Company's
TPTs incorporate a tumor-targeting antibody fragment and a protein
cytotoxic payload into a single protein molecule in order to achieve
focused tumor cell killing. The Company believes its TPT approach offers
significant advantages in treating cancer over existing antibody drug
conjugate technologies. The Company believes its TPTs provide effective
tumor targeting with broader cancer cell-killing properties than are
achievable with small molecule payloads that require tumor cell
proliferation and face multi-drug resistance mechanisms. Additionally,
the Company believes that its TPT's cancer cell-killing properties
promote an anti-tumor immune response that will potentially combine well
with immune oncology drugs such as checkpoint inhibitors. For more
information please refer to the Company's website at www.elevenbio.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005550/en/
Source: Eleven Biotherapeutics, Inc.
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200